BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1990 related articles for article (PubMed ID: 30886395)

  • 1. Immunotherapy in colorectal cancer: rationale, challenges and potential.
    Ganesh K; Stadler ZK; Cercek A; Mendelsohn RB; Shia J; Segal NH; Diaz LA
    Nat Rev Gastroenterol Hepatol; 2019 Jun; 16(6):361-375. PubMed ID: 30886395
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Expanding the Scope of Immunotherapy in Colorectal Cancer: Current Clinical Approaches and Future Directions.
    Kreidieh M; Mukherji D; Temraz S; Shamseddine A
    Biomed Res Int; 2020; 2020():9037217. PubMed ID: 32090113
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Perspectives on Treatment of Metastatic Colorectal Cancer with Immune Checkpoint Inhibitor Therapy.
    Morse MA; Hochster H; Benson A
    Oncologist; 2020 Jan; 25(1):33-45. PubMed ID: 31383813
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Deficient Mismatch Repair and the Role of Immunotherapy in Metastatic Colorectal Cancer.
    Quiroga D; Lyerly HK; Morse MA
    Curr Treat Options Oncol; 2016 Aug; 17(8):41. PubMed ID: 27315067
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Current advancements and future perspectives of immunotherapy in colorectal cancer research.
    Kishore C; Bhadra P
    Eur J Pharmacol; 2021 Feb; 893():173819. PubMed ID: 33347822
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Immunotherapy efficacy on mismatch repair-deficient colorectal cancer: From bench to bedside.
    Lizardo DY; Kuang C; Hao S; Yu J; Huang Y; Zhang L
    Biochim Biophys Acta Rev Cancer; 2020 Dec; 1874(2):188447. PubMed ID: 33035640
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Towards exertion of immunotherapeutics in the treatment of colorectal cancer; adverse sides, challenges, and future directions.
    Pan W; Zhao J; Zhang S; Chen X; Liang W; Li Q
    Int Immunopharmacol; 2021 Dec; 101(Pt B):108337. PubMed ID: 34775366
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Tumor-Infiltrating Lymphocytes in Colorectal Cancer: The Fundamental Indication and Application on Immunotherapy.
    Bai Z; Zhou Y; Ye Z; Xiong J; Lan H; Wang F
    Front Immunol; 2021; 12():808964. PubMed ID: 35095898
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cell-based immunotherapy approaches for colorectal cancer: main achievements and challenges.
    Shahnazari M; Samadi P; Pourjafar M; Jalali A
    Future Oncol; 2021 Aug; 17(24):3253-3270. PubMed ID: 34156258
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Immunotherapy in colorectal cancer: current achievements and future perspective.
    Fan A; Wang B; Wang X; Nie Y; Fan D; Zhao X; Lu Y
    Int J Biol Sci; 2021; 17(14):3837-3849. PubMed ID: 34671202
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Neoadjuvant Immunotherapy for MSI-H/dMMR Locally Advanced Colorectal Cancer: New Strategies and Unveiled Opportunities.
    Zhang X; Wu T; Cai X; Dong J; Xia C; Zhou Y; Ding R; Yang R; Tan J; Zhang L; Zhang Y; Wang Y; Dong C; Li Y
    Front Immunol; 2022; 13():795972. PubMed ID: 35371084
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Current Microsatellite Instability Testing in Management of Colorectal Cancer.
    Sun BL
    Clin Colorectal Cancer; 2021 Mar; 20(1):e12-e20. PubMed ID: 32888812
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Immunotherapy in colorectal cancer: is the long-awaited revolution finally happening?
    Arrichiello G; Poliero L; Borrelli C; Paragliola F; Nacca V; Napolitano S; Corte CMD; Martini G; Martinelli E
    Cancer Treat Res Commun; 2021; 28():100442. PubMed ID: 34391139
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Is There a Role for Programmed Death Ligand-1 Testing and Immunotherapy in Colorectal Cancer With Microsatellite Instability? Part I-Colorectal Cancer: Microsatellite Instability, Testing, and Clinical Implications.
    Marginean EC; Melosky B
    Arch Pathol Lab Med; 2018 Jan; 142(1):17-25. PubMed ID: 29144791
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Beyond Microsatellite Instability: Evolving Strategies Integrating Immunotherapy for Microsatellite Stable Colorectal Cancer.
    Pecci F; Cantini L; Bittoni A; Lenci E; Lupi A; Crocetti S; Giglio E; Giampieri R; Berardi R
    Curr Treat Options Oncol; 2021 Jun; 22(8):69. PubMed ID: 34110510
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cost-effectiveness of pembrolizumab for the first-line treatment of patients with unresectable or metastatic MSI-H/dMMR colorectal cancer in the United States.
    Aguiar-Ibáñez R; Hardern C; van Hees F; Lee D; Patel A; Chhabra N; Baluni G; Amonkar M; Lai Y; Xu R; Massaad R; Fogelman D
    J Med Econ; 2022; 25(1):469-480. PubMed ID: 35184650
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinical Development of Immunotherapy for Deficient Mismatch Repair Colorectal Cancer.
    Thomas J; Leal A; Overman MJ
    Clin Colorectal Cancer; 2020 Jun; 19(2):73-81. PubMed ID: 32173280
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The Role of Immune Checkpoint Inhibitors in Colorectal Adenocarcinoma.
    Almquist DR; Ahn DH; Bekaii-Saab TS
    BioDrugs; 2020 Jun; 34(3):349-362. PubMed ID: 32246441
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Immunotherapy, Inflammation and Colorectal Cancer.
    Lichtenstern CR; Ngu RK; Shalapour S; Karin M
    Cells; 2020 Mar; 9(3):. PubMed ID: 32143413
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Heterogeneity of Mismatch Repair Status and Microsatellite Instability between Primary Tumour and Metastasis and Its Implications for Immunotherapy in Colorectal Cancers.
    Evrard C; Messina S; Sefrioui D; Frouin É; Auriault ML; Chautard R; Zaanan A; Jaffrelot M; De La Fouchardière C; Aparicio T; Coriat R; Godet J; Silvain C; Randrian V; Sabourin JC; Guimbaud R; Miquelestorena-Standley E; Lecomte T; Moulin V; Karayan-Tapon L; Tachon G; Tougeron D
    Int J Mol Sci; 2022 Apr; 23(8):. PubMed ID: 35457245
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 100.